期刊
FRONTIERS IN MICROBIOLOGY
卷 13, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fmicb.2022.927031
关键词
heterologous prime-boost; Bacille Calmette-Guerin; DNA vaccine; Rv2299c; Mycobacterium tuberculosis
类别
资金
- National Key Research and Development Program of China
- National Natural and Science Foundation of China
- Shanghai Science and Technology Commission
- [2021YFC2301503]
- [82171815]
- [82171739]
- [81873884]
- [20Y11903400]
This study examined the ability of a DNA vaccine expressing a fusion of antigens Rv2299c and Ag85A to boost BCG immunity and protection against tuberculosis. The results showed that the DNA boost significantly amplified Th1-type cell-mediated immunity and reduced bacterial loads and histological damage in the lung.
The development of heterologous prime-boost regimens utilizing Bacille Calmette-Guerin (BCG) as the priming vaccine is a promising approach to improve the efficacy of vaccination against tuberculosis (TB). In this study, we examined the ability of a DNA vaccine that expressed a fusion of antigens Rv2299c and Ag85A to boost BCG immunity and protection against Mycobacterium tuberculosis (Mtb) in Balb/c mice. The fusion DNA vaccine was moderately immunogenic and afforded some protection when used on its own. After a priming BCG vaccination, the DNA boost significantly amplified Th1-type cell-mediated immunity compared to that resulting from either BCG or DNA immunization. In the DNA-boosted mice, Ag-specific CD4(+) and CD8(+) T cells that were mono-positive for IFN-gamma alone were the most prominently expanded in infected lungs. The protective efficacy afforded by BCG against challenge infection was greatly improved by the DNA boost; bacterial loads were significantly reduced in both spleen and lung and histological damage in the lung was less. The use of a DNA vaccine containing the fusion antigens Rv2299c and Ag85A to boost BCG may be a good choice for the rational design of an efficient vaccination strategy against TB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据